Molecular Partners Ag (MOLN) Assets Average (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Assets Average of $56033.7 for Q1 2026, down 100.0% year-on-year from $78.6 billion in Q1 2025, and down 20.14% on a QoQ basis from $70163.8 in Q4 2025.
Molecular Partners Ag (MOLN) Assets Average (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Assets Average for 6 consecutive years, with $56033.7 the latest figure, recorded in Q1 2026.
- Quarterly Assets Average fell 100.0% year-over-year to $56033.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56033.7 (down 100.0% YoY) and the FY2025 annual result came in at $90.5 million, down 55.27% from the prior year.
- Assets Average retreated to $56033.7 in Q1 2026 per MOLN's latest filing, from $70163.8 in the prior quarter.
- Over the last five years, Assets Average for MOLN reached as high as $169.0 billion in Q2 2022 and fell as low as $56033.7 in Q1 2026.
- A 5-year average of $99.4 billion and a median of $106.4 billion in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 51.56% — and 2026, when it tumbled 100.0%.
- Year by year, Assets Average stood at $145.7 billion in 2022, then slipped by 15.18% to $123.6 billion in 2023, then decreased by 27.91% to $89.1 billion in 2024, then tumbled by 100.0% to $70163.8 in 2025, then fell by 20.14% to $56033.7 in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $56033.7, $70163.8, and $70174.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 56,033.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,033.71 |
| Dec 31, 2025 | 70,163.77 |
| Sep 30, 2025 | 70,174.93 |
| Jun 30, 2025 | 78.47 Bn |
| Mar 31, 2025 | 78.56 Bn |
| Dec 31, 2024 | 89.09 Bn |
| Sep 30, 2024 | 89.09 Bn |
| Jun 30, 2024 | 106.42 Bn |
| Mar 31, 2024 | 106.43 Bn |
| Dec 31, 2023 | 123.58 Bn |
| Sep 30, 2023 | 123.60 Bn |
| Jun 30, 2023 | 132.32 Bn |
| Mar 31, 2023 | 132.33 Bn |
| Dec 31, 2022 | 145.70 Bn |
| Sep 30, 2022 | 145.72 Bn |
| Jun 30, 2022 | 168.99 Bn |
| Mar 31, 2022 | 168.93 Bn |
| Dec 31, 2021 | 96.14 Bn |